Galectin Therapeutics Inc. (NASDAQ:GALT) major shareholder Fund L.P. 10X sold 10,000 shares of the business’s stock in a transaction on Thursday, April 1st. The stock was sold at an average price of $2.16, for a total value of $21,600.00. The sale was disclosed in a filing with the SEC, which is accessible through this link. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.
Fund L.P. 10X also recently made the following trade(s):
- On Tuesday, February 2nd, Fund L.P. 10X sold 10,000 shares of Galectin Therapeutics stock. The stock was sold at an average price of $2.04, for a total value of $20,400.00.
Shares of GALT stock opened at $2.38 on Thursday. The firm has a market capitalization of $136.03 million, a P/E ratio of -6.10 and a beta of 2.04. Galectin Therapeutics Inc. has a twelve month low of $1.65 and a twelve month high of $3.85. The stock’s fifty day simple moving average is $2.26 and its 200 day simple moving average is $2.45.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. FormulaFolio Investments LLC bought a new stake in shares of Galectin Therapeutics in the 4th quarter valued at about $28,000. Renaissance Technologies LLC bought a new stake in shares of Galectin Therapeutics in the 4th quarter valued at about $35,000. Raymond James Financial Services Advisors Inc. bought a new stake in shares of Galectin Therapeutics in the 4th quarter valued at about $41,000. The Manufacturers Life Insurance Company grew its position in shares of Galectin Therapeutics by 23.4% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 26,819 shares of the company’s stock valued at $72,000 after buying an additional 5,093 shares during the last quarter. Finally, Wells Fargo & Company MN lifted its stake in shares of Galectin Therapeutics by 69.1% in the 4th quarter. Wells Fargo & Company MN now owns 96,815 shares of the company’s stock valued at $217,000 after purchasing an additional 39,571 shares during the period. Hedge funds and other institutional investors own 17.58% of the company’s stock.
About Galectin Therapeutics
Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is (GR-MD-02) belapectin galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer.
Further Reading: Determine Your Level of Risk Tolerance
Receive News & Ratings for Galectin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.